Prelude Therapeutics (PRLD) Net Cash Flow Growth (3y) (2022 - 2026)
Prelude Therapeutics (PRLD) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
723,416.35 Bn |
723,416.32 Bn |
- |
- |
| 2 |
Belite Bio |
57,340.00 Bn |
57,340.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
19,125.08 Bn |
19,125.08 Bn |
- |
- |
| 4 |
Legend Biotech |
3,262.00 Bn |
3,261.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,789.67 Bn |
1,789.67 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,480.39 Bn |
1,480.37 Bn |
- |
- |
| 7 |
Psyence Biomedical |
241.78 Bn |
241.78 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.54 Bn |
106.29 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
94.26 Bn |
94.26 Bn |
- |
- |
| 10 |
Prelude Therapeutics |
314.40 Mn |
169.80 Mn |
- |
-2.86% |
| Date | Value |
|---|
| Mar 31, 2026 |
-2.86% |
| Dec 31, 2025 |
16.93% |
| Sep 30, 2025 |
151.64% |
| Jun 30, 2025 |
-150.10% |
| Mar 31, 2025 |
11.96% |
| Dec 31, 2024 |
27.08% |
| Sep 30, 2024 |
61.01% |
| Jun 30, 2024 |
29.21% |
| Mar 31, 2024 |
-26.08% |
| Dec 31, 2023 |
36.98% |
| Sep 30, 2023 |
-27.06% |
| Jun 30, 2023 |
42.85% |
| Mar 31, 2023 |
-37.95% |
| Dec 31, 2022 |
-34.71% |
